Evidence map›Paper›PMID 41892053›Full record

ReviewBiosensors2026

Progress in Machine Learning-Assisted Biosensors for Alzheimer's Disease.

Yan Feng, Changdong Chen

Abstract readReview
In one paragraph

Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yan FengSchool of Artificial Intelligence, Pingdingshan University, Pingdingshan 467000, China.
Changdong ChenSchool of Chemistry and Environmental Engineering, Pingdingshan University, Pingdingshan 467000, China.

Funding

Science and Technology Development Program of Henan Province 252102240080
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common cause of dementia, affecting 55 million people worldwide. Its characteristics include the accumulation of senile plaques and neurofibrillary tangles. This disease is associated with changes in the concentration of AD biomarkers, such as microRNAs, amyloid peptides, Tau protein, and neurofilament light chains. Due to the fact that neuropathological processes begin decades before the onset of cognitive symptoms, accurate detection of AD biomarkers is crucial for its early diagnosis. The combination of analytical techniques and machine learning methods plays a crucial role in medical innovation. Recently, efforts have been made to develop machine learning-assisted biosensors for AD diagnosis. This article provides an overview of the progress in machine learning-assisted sensing of AD biomarkers in bodily fluids. It mainly includes three parts: machine learning algorithms, machine learning-assisted electrochemical and optical biosensors, and challenges and future perspectives. We believe that this work will contribute to the development of innovative analytical devices based on artificial intelligence for monitoring and managing neurodegenerative diseases.

Indexed as

Alzheimer DiseaseBiosensing TechniquesMachine LearningAlgorithmsBiomarkersElectrochemical TechniquesHumansSoft ComputingBiomarkersAlzheimer’s diseaseelectrochemical biosensorsmachine learningoptical biosensors

Identifiers

PMID41892053
PMCPMC13023455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.